Lipella Pharmaceuticals (LIPO) News Today → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free LIPO Stock Alerts $0.76 0.00 (0.00%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13, 2024 | finance.yahoo.comLipella Pharmaceuticals First Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.19 loss in 1Q 2023)May 8, 2024 | americanbankingnews.comLipella Pharmaceuticals (NASDAQ:LIPO) Trading Down 2.4%April 17, 2024 | finance.yahoo.comLipella Pharmaceuticals Expands its Advisory Board to Include Oncology ExpertiseApril 17, 2024 | globenewswire.comLipella Pharmaceuticals Expands its Advisory Board to Include Oncology ExpertiseApril 5, 2024 | globenewswire.comLipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024April 3, 2024 | markets.businessinsider.comLipella Pharmaceuticals Announces Type C Meeting For LP-10 - Quick FactsApril 3, 2024 | globenewswire.comLipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic CystitisMarch 20, 2024 | insidertrades.comLipella Pharmaceuticals Inc. (NASDAQ:LIPO) Insider Jonathan H. Kaufman Purchases 30,000 SharesMarch 7, 2024 | finance.yahoo.comPRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare DiseaseMarch 5, 2024 | markets.businessinsider.comLipella Pharma's IND Application For LP-410 Gets FDA's ApprovalMarch 3, 2024 | morningstar.comLipella Pharmaceuticals Inc Ordinary Shares LIPOMarch 1, 2024 | finance.yahoo.comLipella Pharmaceuticals Full Year 2023 Earnings: US$0.77 loss per share (vs US$0.64 loss in FY 2022)February 20, 2024 | finance.yahoo.comLipella Pharmaceuticals to Present at PropThink Digital Investor ConferenceFebruary 20, 2024 | globenewswire.comLipella Pharmaceuticals to Present at PropThink Digital Investor ConferenceFebruary 9, 2024 | finance.yahoo.comLipella Pharmaceuticals Inc. (LIPO)December 20, 2023 | finanznachrichten.deLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones AccomplishedDecember 20, 2023 | finance.yahoo.comLipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones AccomplishedDecember 9, 2023 | morningstar.comLipella Pharmaceuticals Inc Ordinary SharesNovember 10, 2023 | markets.businessinsider.comLipella Pharma: FDA Grants Orphan Designation For LP-310 To Treat Oral Graft-versus-Host DiseaseNovember 10, 2023 | finance.yahoo.comFDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host DiseaseOctober 25, 2023 | finance.yahoo.comLipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq RulesOctober 24, 2023 | finance.yahoo.comLipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq RulesOctober 23, 2023 | finance.yahoo.comLipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo ConferenceOctober 22, 2023 | msn.comLipella Pharmaceuticals stock more than doubles in 3 days as FDA approves IND for OLP treatmentOctober 20, 2023 | benzinga.comWhat's Going On With Lipella Pharmaceuticals Stock?October 20, 2023 | msn.comInvestors Remain Cautious Over Fed Moves, Setting Wall Street Up for Lower OpenOctober 20, 2023 | benzinga.comGold Rises Over 1%; Schlumberger Shares Fall After Q3 ResultsOctober 20, 2023 | marketwatch.comLipella Pharmaceuticals Shares Soar on FDA ApprovalOctober 20, 2023 | finance.yahoo.comLipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen PlanusOctober 4, 2023 | msn.comU.S. shares higher at close of trade; Dow Jones Industrial Average up 0.39%October 4, 2023 | msn.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.39%September 21, 2023 | finance.yahoo.comLipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and NephrologySeptember 7, 2023 | investing.comLipella Pharmaceuticals Inc (LIPO)June 13, 2023 | finance.yahoo.comLipella Pharmaceuticals: Addressing Significant Unmet Need for Cancer Survivors, Delivering Long Term Value for ShareholdersMay 15, 2023 | finanznachrichten.deLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate UpdateMay 15, 2023 | msn.comLipella reports Q1 resultsMay 15, 2023 | finance.yahoo.comLipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate UpdateMay 14, 2023 | finance.yahoo.comLipella Pharmaceuticals First Quarter 2023 Earnings: US$0.19 loss per share (vs US$0.19 loss in 1Q 2022)May 1, 2023 | finance.yahoo.comLipella Pharmaceuticals Delivers Late-Breaking Presentation at the American Urological Association Annual MeetingApril 17, 2023 | finance.yahoo.comLipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSiteApril 5, 2023 | finance.yahoo.comLipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast AgentMarch 31, 2023 | finanznachrichten.deLipella Pharmaceuticals Inc.: Lipella Provides Business Update and Reports 2022 Financial ResultsMarch 31, 2023 | finance.yahoo.comLipella Provides Business Update and Reports 2022 Financial ResultsMarch 16, 2023 | finance.yahoo.comLipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial; Announces Late-Breaking Presentation at the Annual Meeting of the American Urological AssociationMarch 1, 2023 | finance.yahoo.comLipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory BoardFebruary 21, 2023 | dailymail.co.ukThe truth about liposuctionFebruary 21, 2023 | finance.yahoo.comLipella Announces Closing of Initial Public Offering for Gross Proceeds of $7 MillionFebruary 21, 2023 | finance.yahoo.comLipella Pharmaceuticals to Present at January 2023 Biotech Showcase in San FranciscoFebruary 21, 2023 | finance.yahoo.comLipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10January 11, 2023 | marketbeat.comTrading was temporarily halted for "LIPO" at 09:01 AM with a stated reason of "LULD pause." Get Lipella Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter. Email Address Invest in the "Trojan Horse" of Alzheimer's Treatment (Ad)This one tiny Micro-Cap is at the forefront of what may be the most significant development in healthcare since the discovery of antibiotics. Click here and learn how you can invest in this incredible opportunity>>> LIPO Media Mentions By Week LIPO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LIPO News Sentiment▼0.780.54▲Average Medical News Sentiment LIPO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LIPO Articles This Week▼40▲LIPO Articles Average Week Get Lipella Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CPHI News Today DRUG News Today PTPI News Today KZIA News Today GTBP News Today ZVSA News Today SEEL News Today NEXI News Today THAR News Today XCUR News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LIPO) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the Markets348 million Americans lives to END as we know it?The Oxford ClubGold Set to EXPLODE!Gold Safe Exchange[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsHow Biden has already won 2024Porter & CompanyA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
